Cytoreductive Nephrectomy: Assessing the Generalizability of the CARMENA Trial to Real-world National Cancer Data Base Cases

Eur Urol. 2019 Feb;75(2):352-353. doi: 10.1016/j.eururo.2018.10.054. Epub 2018 Nov 9.
No abstract available

Publication types

  • Comparative Study
  • Letter

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Antineoplastic Agents / adverse effects
  • Antineoplastic Agents / therapeutic use*
  • Carcinoma, Renal Cell / mortality
  • Carcinoma, Renal Cell / secondary
  • Carcinoma, Renal Cell / therapy*
  • Chemotherapy, Adjuvant
  • Clinical Trials, Phase III as Topic* / methods
  • Cytoreduction Surgical Procedures* / adverse effects
  • Cytoreduction Surgical Procedures* / mortality
  • Databases, Factual*
  • Female
  • Humans
  • Kidney Neoplasms / mortality
  • Kidney Neoplasms / pathology
  • Kidney Neoplasms / therapy*
  • Male
  • Middle Aged
  • Multicenter Studies as Topic* / methods
  • Nephrectomy* / adverse effects
  • Nephrectomy* / mortality
  • Research Design
  • Retrospective Studies
  • Sunitinib / adverse effects
  • Sunitinib / therapeutic use*
  • Time Factors
  • Treatment Outcome

Substances

  • Antineoplastic Agents
  • Sunitinib